Altimmune to Announce First Quarter 2018 Financial Results on May 16
Tuesday, May 08, 2018 8:00:00 AM ET
GAITHERSBURG, Md., May 08, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the first quarter ended March 31, 2018 before the market open and host a conference call on Wednesday, May 16.
Conference Call Details
Date: Wednesday, May 16
Time: 8:30am Eastern Time
Conference ID: 1336227
Replays, Available through May 30th:
Replay PIN: 1336227
Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease including NasoVAX, a Phase 2 seasonal influenza vaccine candidate, and HepTcell, a Phase 1 immunotherapeutic candidate for the potential cure of chronic hepatitis B. The company also has two United States government funded, next-generation anthrax vaccine candidates that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines.
President and CEO
LifeSci Advisors, LLC
Source: Altimmune, Inc.